1118 Blackstone Galakatos
BioCentury & Getty Images

Finance

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

Life sciences group seeking to own stakes in drugs, make growth-stage bets

The firm’s life sciences group is seeking to own stakes in commercial-stage drugs and make growth-stage bets.

Nov 19, 2020 | 1:38 AM GMT

Two years after Clarus’ acquisition by Blackstone, the life sciences investor is taking advantage of its parent company’s scale to stretch beyond its initial sweet spot. The firm that specialized in risk-sharing deals is now seeking to invest in products it can shepherd through to commercialization, as

Read the full 1004 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE